Table 1.
Patients | ||
---|---|---|
Characteristic | n | % |
Full cohort, n | 295 | 100 |
Recipient age, median (range) | 66 (6-76) | |
Recipient sex | ||
Female | 117 | 40 |
Male | 178 | 60 |
HCT-CI score | ||
0 | 83 | 28 |
1-2 | 81 | 27 |
3+ | 120 | 40 |
Missing | 11 | 4 |
Type of AML (clinically defined) | ||
De novo | 173 | 59 |
Secondary | 91 | 31 |
Therapy-related | 31 | 11 |
Cytogenetics * | ||
Normal | 136 | 46 |
Core binding factor | 6 | 2 |
Complex karyotype | 41 | 14 |
Other | 112 | 38 |
2017 ELN risk group | ||
Favorable | 53 | 18 |
Intermediate | 85 | 29 |
Adverse | 152 | 52 |
Missing | 5 | 2 |
Initial therapy | ||
Intensive induction | 249 | 84 |
Non-intensive induction | 46 | 16 |
Reinduction | ||
Yes | 90 | 31 |
No | 204 | 69 |
Missing | 1 | 0.3 |
Remission quality | ||
CR with hematologic recovery | 225 | 75 |
CRi | 67 | 23 |
Missing | 1 | 0.3 |
Donor type | ||
Matched related | 54 | 18 |
Matched unrelated | 154 | 52 |
Mismatch related | 7 | 2 |
Mismatch unrelated | 29 | 10 |
Haploidentical | 51 | 17 |
Conditioning regimen | ||
Myeloablative | 28 | 9 |
Reduced intensity | 267 | 91 |
T-cell depletion | 25 | 9 |
Stem cell source | ||
Peripheral blood | 216 | 73 |
Bone marrow | 71 | 24 |
Umbilical cord blood | 8 | 3 |
Shown are the pretransplant characteristics of the 295 patients included in the cohort. HCT-CI: hematopoietic cell transplant comorbidity index score. CRi denotes complete remission with incomplete recovery of at least 1 hematopoietic cell lineage.
ELN, European Leukemia Network.
Core binding factor: inv(16) or t(8;21); complex karyotype: 3 or more chromosomal abnormalities within a single clone.